ITGA3

Summary

ITGA3 (integrin subunit alpha 3, HGNC:6139) is a protein-coding gene on chromosome 17q21.33, encoding Integrin alpha-3 (P26006). Integrin alpha-3/beta-1 is a receptor for fibronectin, laminin, collagen, epiligrin, thrombospondin and CSPG4.

The gene encodes a member of the integrin alpha chain family of proteins. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain that function as cell surface adhesion molecules. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha 3 subunit. This subunit joins with a beta 1 subunit to form an integrin that interacts with extracellular matrix proteins including members of the laminin family. Expression of this gene may be correlated with breast cancer metastasis.

Source: NCBI Gene 3675 — RefSeq curated summary.

At a glance

• Gene–disease (curated): epidermolysis bullosa, junctional 7, with interstitial lung disease and nephrotic syndrome (Definitive, ClinGen)
• Clinical variants (ClinVar): 625 total — 5 pathogenic, 22 likely-pathogenic
• Phenotypes (HPO): 35
• Druggable target: yes
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity no evidence
• MANE Select transcript: NM_002204

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6139
Approved symbol	ITGA3
Name	integrin subunit alpha 3
Location	17q21.33
Locus type	gene with protein product
Status	Approved
Aliases	CD49c, VLA3a, VCA-2, GAP-B3
Ensembl gene	ENSG00000005884
Ensembl biotype	protein_coding
OMIM	605025
Entrez	3675

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 9 retained_intron, 7 protein_coding, 3 nonsense_mediated_decay

ENST00000007722, ENST00000320031, ENST00000504417, ENST00000505306, ENST00000505552, ENST00000505612, ENST00000506401, ENST00000506437, ENST00000506827, ENST00000507771, ENST00000508100, ENST00000510809, ENST00000512553, ENST00000514834, ENST00000515147, ENST00000570989, ENST00000876971, ENST00000876972, ENST00000876973

RefSeq mRNA: 1 — MANE Select: NM_002204 NM_002204

CCDS: CCDS11558

Canonical transcript exons

ENST00000320031 — 26 exons

Exon	Start	End
ENSE00000925071	50077379	50077447
ENSE00000925073	50076974	50077121
ENSE00002028816	50056110	50056645
ENSE00002044743	50089110	50090481
ENSE00003459318	50081310	50081408
ENSE00003465654	50075459	50075526
ENSE00003471267	50064077	50064204
ENSE00003474704	50078824	50078926
ENSE00003529186	50076584	50076681
ENSE00003532073	50078207	50078284
ENSE00003557526	50074448	50074534
ENSE00003561204	50073916	50074004
ENSE00003600504	50071311	50071518
ENSE00003603461	50078046	50078125
ENSE00003610389	50088225	50088366
ENSE00003617587	50074144	50074280
ENSE00003639446	50075599	50075735
ENSE00003641332	50071986	50072182
ENSE00003644478	50080262	50080375
ENSE00003650723	50064528	50064607
ENSE00003657377	50079435	50079557
ENSE00003661042	50068056	50068305
ENSE00003665798	50079076	50079258
ENSE00003682794	50076326	50076475
ENSE00003682928	50087744	50087869
ENSE00003693256	50070844	50070930

Expression profiles

Bgee: expression breadth ubiquitous, 149 present calls, max score 98.50.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 51.1013 / max 551.4505, expressed in 1596 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
161572	31.3519	1497
161569	13.1287	1310
161571	4.0893	1275
161570	1.7322	957
161575	0.4179	248
161568	0.2577	97
208248	0.1236	50

Top tissues by expression

158 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
metanephric glomerulus	UBERON:0004736	98.50	gold quality
right coronary artery	UBERON:0001625	98.32	gold quality
upper lobe of left lung	UBERON:0008952	97.79	gold quality
descending thoracic aorta	UBERON:0002345	97.76	gold quality
metanephros cortex	UBERON:0010533	97.70	gold quality
popliteal artery	UBERON:0002250	97.60	gold quality
tibial artery	UBERON:0007610	97.60	gold quality
right lung	UBERON:0002167	97.44	gold quality
right lobe of thyroid gland	UBERON:0001119	97.43	gold quality
ascending aorta	UBERON:0001496	97.42	gold quality
thoracic aorta	UBERON:0001515	97.42	gold quality
left lobe of thyroid gland	UBERON:0001120	97.36	gold quality
epithelium of bronchus	UBERON:0002031	97.24	gold quality
thyroid gland	UBERON:0002046	97.23	gold quality
left coronary artery	UBERON:0001626	96.66	gold quality
islet of Langerhans	UBERON:0000006	96.49	gold quality
mucosa of stomach	UBERON:0001199	96.35	gold quality
lung	UBERON:0002048	96.30	gold quality
mucosa of transverse colon	UBERON:0004991	95.53	gold quality
right uterine tube	UBERON:0001302	94.98	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	94.82	gold quality
adult mammalian kidney	UBERON:0000082	94.72	gold quality
pituitary gland	UBERON:0000007	94.27	gold quality
kidney	UBERON:0002113	94.20	gold quality
adenohypophysis	UBERON:0002196	94.11	gold quality
cortex of kidney	UBERON:0001225	94.10	gold quality
duodenum	UBERON:0002114	94.06	gold quality
placenta	UBERON:0001987	93.95	gold quality
transverse colon	UBERON:0001157	93.90	gold quality
left adrenal gland cortex	UBERON:0035825	93.72	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	15.62

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ETS1, HOXD3, IL1B, ITGB8, MYC, SNAI2, SP3, SPI1, TGFB1, YY1

Functional genomics

ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• Data demonstrate that multiple tetraspanin (transmembrane 4 superfamily) proteins such as CD151 are palmitoylated, and that palmitoylation is not required for cd151-alpha3beta1 integrin association. (PMID:11907260)
• Human prostate tumors display on their cell surface the alpha6beta1 and/or alpha3beta1 integrins (PMID:11988844)
• initial adhesion of endometrial cells to mesothelium is not mediated by alpha(3)beta(1)integrin (PMID:12372459)
• Integrin-alpha 3 sub-unit participates the process of regulating growth of meningiomas. (PMID:12452046)
• expression of alpha3 integrin subunit is responsible for differentiation-associated changes in cells behavior in terminally differentiated oral keratinocytes (PMID:12699087)
• signaling through both constitutively expressed alpha2 integrin and Matrigel-induced alpha3 integrin expression is required to acquire a differentiated phenotype in Caco-2 cells. (PMID:12717361)
• Data show that macrophage stimulating protein (MSP) and its receptor (Ron) induce phosphorylation of both Ron and alpha6beta4 integrin, and result in activation of alpha3beta1 integrin. (PMID:12919677)
• Disulfide bonding patterns of the integrin alpha 3 chain are described; the alpha chain displays differences in the disulfide patterns of those bonds near their C-terminal regions linking the heavy and light chains. (PMID:14596610)
• Data demonstrate that alpha6beta4 integrin mediates pancreatic epithelial cell adhesion to Netrin-1, whereas recruitment of alpha6beta4 and alpha3beta1 regulate the migration of putative pancreatic progenitors on Netrin-1. (PMID:14602071)
• ligand-binding specificities of integrin alpha3beta1 and alpha6beta1 (PMID:14607975)
• alpha3beta1 integrin binding to laminin-5 depends on its proteolytic processing (PMID:14612440)
• results suggest that a direct interaction occurs between the Adenovirus penton base protein and the integrin receptor alpha3beta1 in vitro and in vivo (PMID:14645603)
• results show how laterally associated EWI-2 might regulate alpha3beta1 function in disease and development, and demonstrate how tetraspanin proteins can assemble multiple nontetraspanin proteins into functional complexes (PMID:14662754)
• alpha3beta1, alpha4beta1 and alphaVbeta1 integrins may play an important role in the implantation process (PMID:14666169)
• Data suggest that the early arrest of tumor cells in the pulmonary vasculature through interaction of alpha3beta1 integrin with laminin-5 in exposed basement membrane provides a basis for cell arrest during pulmonary metastasis. (PMID:15024036)
• Alpha 3 beta 1 integrin is necessary and sufficient for maximal keratinocyte survival on laminin-5. (PMID:15280429)
• cAMP-Epac-Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the alpha3beta1 integrin but not the alpha6beta4 integrin (PMID:15302884)
• Results indicate that CD151 association modulates the ligand-binding activity of integrin alpha3beta1 through stabilizing its activated conformation not only with purified proteins but also in a physiological context. (PMID:15677332)
• Beta ig-h3 induces keratinocyte differentiation via modulation of involucrin and transglutaminase expression through the integrin alpha3beta1 and the phosphatidylinositol 3-kinase/Akt signaling pathway (PMID:15805105)
• KSHV gB can activate VEGFR-3 on the microvascular endothelium and modulate endothelial cell migration and proliferation via an interaction between the alpha3beta1 integrin and the VEGFR-3 receptor (PMID:15878864)
• alpha3beta1 integrin binding results in a suppression of the interleukin-1 signaling pathway leading to the activation of NF-(kappa)B (PMID:15919367)
• alpha3, alpha5, and alpha6 beta1 integrins are expressed in ductal cells at 8 weeks, before glucagon- and insulin-immunoreactive cells bud off in fetal pancrea. (PMID:15983209)
• the signaling network involving Smad-dependent TGFbeta, PKCdelta, and integrin alpha2beta1/alpha3beta1, regulates cell spreading, motility, and invasion of the SNU16mAd gastric carcinoma cell variant (PMID:16055706)
• phenotypic conversion and reversion of bladder cancer cells is controlled by a glycosynapse 3 microdomain through GM3-mediated interaction of alpha3beta1 integrin with CD9 (PMID:16103120)
• localized expression of the integrin alpha3 protein is regulated at the level of RNA localization by MBNL1; integrin alpha3 transcripts are physically associated with MLP1 in cells and MLP1 binds to a specific ACACCC motif in the integrin alpha3 3’ UTR (PMID:16273094)
• Thus, the integrin/Src pathway negatively regulates the induction of long-term plasticity at inhibitory synapses on a cerebellar Purkinje cells. (PMID:16307893)
• Data show that alpha6 and alpha3 integrin subunits interact with laminin 5 to increase expression of E-cadherin, and suggest that phosphoinositide 3-kinase (PI 3-kinase) activation plays a key role in this cross-talk. (PMID:16339173)
• Our data show that alpha3beta1 integrin function may be altered by glycosylation, that both subunits contribute to these changes, and glycosylation may be considered a newly found mechanism in the regulation of integrin function. (PMID:16373174)
• Results suggest that loss of E-cadherin function is linked to regulation of cell-cell and cell-matrix adhesion, based in part on cell surface expression of alpha2, alpha3 and beta1 integrins. (PMID:16390868)
• decreased podocyte expression of alpha3beta1 integrins is closely related with podocyte depletion, glomerular sclerosis, and daily protein loss in patients with primary focal glomerulosclerosis (PMID:16459165)
• TGF-beta1 stimulates hepatoma cells to express a higher level of alpha3 integrin by transcriptional upregulation via Ets transcription factors and to exhibit a more invasive phenotype. (PMID:16475024)
• This study supports matrix-induced clustering of alpha3beta1 integrin promotes uPAR/alpha3beta1 interaction; potentiating cellular signal transduction pathways culminating in activation of uPA expression and enhanced uPA-dependent invasive behavior. (PMID:16510444)
• EWI proteins EWI-2 and EWI-F, alpha3beta1 and alpha6beta4 integrins, and protein palmitoylation have contrasting effects on cell surface CD9 organization (PMID:16537545)
• Both integrin alpha3beta1- and alpha6beta4-dependent cell adhesion to laminin-5 were also impaired in CD151-silenced cells. (PMID:16571677)
• Slug regulates integrin alpha3, beta1, and beta4 expression and cell proliferation in human epidermal keratinocytes (PMID:16707493)
• integrin alpha3beta1 is a receptor for the alpha3NC1 domain and transdominantly inhibits integrin alphavbeta3 activation (PMID:16731529)
• Acquisition of multiple antitumor drugs was accompanied by a drastically reduced expression of alpha3beta1 in the adenocarcinoma cells. (PMID:16732726)
• Binding of Borrelia burgdorferi to integrin alpha 3 beta 1 results in release of inflammatory mediators from human chondrocytes and is proposed as a Toll-like receptor-independent pathway for activation of the innate immune response. (PMID:16785564)
• Chondrocytes with low chondrogenic capacity expressed higher levels of IGF-1, MMP-2, aggrecanase 2, while chondrocytes with high chondrogenic capacity expressed higher levels of CD44, CD151, and CD49c. (PMID:17265493)
• Integrin-mediated adhesion via alpha3beta1, but not alpha6beta4 integrin, supports cell survival through EGFR by signaling downstream to Erk. (PMID:17475774)

Cross-species orthologs

11 orthologs

Organism	Symbol	Gene ID
danio_rerio	itga3b	ENSDARG00000012824
danio_rerio	itga3a	ENSDARG00000037917
mus_musculus	Itga3	ENSMUSG00000001507
rattus_norvegicus	Itga3	ENSRNOG00000004276
drosophila_melanogaster	if	FBGN0001250
drosophila_melanogaster	mew	FBGN0004456
drosophila_melanogaster	ItgaPS4	FBGN0034005
drosophila_melanogaster	ItgaPS5	FBGN0034880
drosophila_melanogaster	scb	FBGN0286785
caenorhabditis_elegans		WBGENE00002081
caenorhabditis_elegans		WBGENE00003929

Paralogs (17): ITGAL (ENSG00000005844), ITGA2B (ENSG00000005961), ITGA8 (ENSG00000077943), ITGAE (ENSG00000083457), ITGA6 (ENSG00000091409), ITGA4 (ENSG00000115232), ITGA7 (ENSG00000135424), ITGA11 (ENSG00000137809), ITGAV (ENSG00000138448), ITGAX (ENSG00000140678), ITGA10 (ENSG00000143127), ITGA9 (ENSG00000144668), ITGAD (ENSG00000156886), ITGA5 (ENSG00000161638), ITGA2 (ENSG00000164171), ITGAM (ENSG00000169896), ITGA1 (ENSG00000213949)

Protein

Protein identifiers

Integrin alpha-3 — P26006 (reviewed: P26006)

Alternative names: CD49 antigen-like family member C, FRP-2, Galactoprotein B3, VLA-3 subunit alpha

All UniProt accessions (7): P26006, A0A140VJM0, D6R9X8, H0YA32, H0YA49, K7EMU3, K7EQJ2

UniProt curated annotations — full annotation on UniProt →

Function. Integrin alpha-3/beta-1 is a receptor for fibronectin, laminin, collagen, epiligrin, thrombospondin and CSPG4. Integrin alpha-3/beta-1 provides a docking site for FAP (seprase) at invadopodia plasma membranes in a collagen-dependent manner and hence may participate in the adhesion, formation of invadopodia and matrix degradation processes, promoting cell invasion. Alpha-3/beta-1 may mediate with LGALS3 the stimulation by CSPG4 of endothelial cells migration. (Microbial infection) Integrin ITGA3:ITGB1 may act as a receptor for R.delemar CotH7 in alveolar epithelial cells, which may be an early step in pulmonary mucormycosis disease progression.

Subunit / interactions. Heterodimer of an alpha and a beta subunit. The alpha subunit is composed of a heavy and a light chain linked by a disulfide bond. Alpha-3 associates with beta-1. Interacts with HPS5. Interacts with FAP (seprase); the interaction occurs at the cell surface of invadopodia membrane in a collagen-dependent manner.

Subcellular location. Cell membrane. Cell projection. Invadopodium membrane. Filopodium membrane.

Tissue specificity. Isoform 1 is widely expressed. Isoform 2 is expressed in brain and heart. In brain, both isoforms are exclusively expressed on vascular smooth muscle cells, whereas in heart isoform 1 is strongly expressed on vascular smooth muscle cells, isoform 2 is detected only on endothelial vein cells.

Post-translational modifications. Isoform 1, but not isoform 2, is phosphorylated on serine residues. Phosphorylation increases after phorbol 12-myristate 13-acetate stimulation.

Disease relevance. Epidermolysis bullosa, junctional 7, with interstitial lung disease and nephrotic syndrome (JEB7) [MIM:614748] A form of epidermolysis bullosa, a genodermatosis characterized by recurrent blistering, fragility of the skin and mucosal epithelia, and erosions caused by minor mechanical trauma. JEB7 is an autosomal recessive form associated with congenital nephrotic syndrome and interstitial lung disease. The respiratory and renal features predominate, and lung involvement accounts for the lethal course of the disease. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the integrin alpha chain family.

Isoforms (2)

UniProt ID	Names	Canonical?
P26006-2	1, Alpha-3A	yes
P26006-1	2, Alpha-3B

RefSeq proteins (1): NP_002195* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000413	Integrin_alpha	Family
IPR013517	FG-GAP	Repeat
IPR013519	Int_alpha_beta-p	Repeat
IPR013649	Integrin_alpha_Ig-like_1	Domain
IPR018184	Integrin_alpha_C_CS	Conserved_site
IPR028994	Integrin_alpha_N	Homologous_superfamily
IPR032695	Integrin_dom_sf	Homologous_superfamily
IPR048285	Integrin_alpha_Ig-like_2	Domain
IPR048286	Integrin_alpha_Ig-like_3	Domain

Pfam: PF01839, PF08441, PF20805, PF20806

UniProt features (62 total): glycosylation site 14, binding site 13, disulfide bond 9, repeat 7, sequence variant 6, chain 3, region of interest 2, topological domain 2, signal peptide 1, short sequence motif 1, lipid moiety-binding region 1, transmembrane region 1, splice variant 1, mutagenesis site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P26006-F1	83.88	0.45

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (13): 315; 317; 319; 323; 378; 380; 382; 386; 439; 441; 443; 445 …

Post-translational modifications (1): 1016

Disulfide bonds (9): 94–103, 140–162, 185–197, 485–490, 496–550, 615–621, 694–702, 846–904, 911–916

Glycosylation sites (14): 86, 107, 265, 500, 511, 573, 605, 656, 697, 841, 857, 926, 935, 969

Mutagenesis-validated functional residues (1):

Position	Phenotype
1016	abolishes palmitoylation.

Function

Pathways and Gene Ontology

Reactome pathways

11 pathways

ID	Pathway
R-HSA-210991	Basigin interactions
R-HSA-216083	Integrin cell surface interactions
R-HSA-3000157	Laminin interactions
R-HSA-8874081	MET activates PTK2 signaling
R-HSA-109582	Hemostasis
R-HSA-1474244	Extracellular matrix organization
R-HSA-162582	Signal Transduction
R-HSA-202733	Cell surface interactions at the vascular wall
R-HSA-6806834	Signaling by MET
R-HSA-8875878	MET promotes cell motility
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases

MSigDB gene sets: 490 (showing top): GOBP_MEMORY, MODULE_52, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, CHIBA_RESPONSE_TO_TSA_UP, GOBP_COGNITION, HNF3ALPHA_Q6, GOBP_BEHAVIOR, GOBP_FORMATION_OF_PRIMARY_GERM_LAYER, MODULE_64, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, GOCC_CELL_SURFACE, GOBP_CELLULAR_COMPONENT_MAINTENANCE, GOBP_NEUROGENESIS, GOBP_REGULATION_OF_WNT_SIGNALING_PATHWAY

GO Biological Process (35): neuron migration (GO:0001764), cell-matrix adhesion (GO:0007160), integrin-mediated signaling pathway (GO:0007229), Rho protein signal transduction (GO:0007266), heart development (GO:0007507), memory (GO:0007613), response to xenobiotic stimulus (GO:0009410), positive regulation of gene expression (GO:0010628), positive regulation of epithelial cell migration (GO:0010634), positive regulation of cell-substrate adhesion (GO:0010811), positive regulation of neuron projection development (GO:0010976), regulation of transforming growth factor beta receptor signaling pathway (GO:0017015), regulation of Wnt signaling pathway (GO:0030111), lung development (GO:0030324), regulation of BMP signaling pathway (GO:0030510), negative regulation of cell projection organization (GO:0031345), response to gonadotropin (GO:0034698), negative regulation of Rho protein signal transduction (GO:0035024), exploration behavior (GO:0035640), skin development (GO:0043588), mesodermal cell differentiation (GO:0048333), leukocyte migration (GO:0050900), maternal process involved in female pregnancy (GO:0060135), nephron development (GO:0072006), dendritic spine maintenance (GO:0097062), renal filtration (GO:0097205), cell-cell adhesion (GO:0098609), synaptic membrane adhesion (GO:0099560), positive regulation of protein localization to plasma membrane (GO:1903078), system process (GO:0003008), cell adhesion (GO:0007155), regulation of signal transduction (GO:0009966), cell differentiation (GO:0030154), system development (GO:0048731), postsynapse organization (GO:0099173)

GO Molecular Function (11): fibronectin binding (GO:0001968), protease binding (GO:0002020), integrin binding (GO:0005178), collagen binding (GO:0005518), protein domain specific binding (GO:0019904), signaling receptor activity (GO:0038023), laminin binding (GO:0043236), metal ion binding (GO:0046872), protein heterodimerization activity (GO:0046982), protein binding (GO:0005515), protein-containing complex binding (GO:0044877)

GO Cellular Component (24): plasma membrane (GO:0005886), focal adhesion (GO:0005925), integrin complex (GO:0008305), external side of plasma membrane (GO:0009897), cell surface (GO:0009986), basolateral plasma membrane (GO:0016323), filopodium membrane (GO:0031527), neuromuscular junction (GO:0031594), integrin alpha3-beta1 complex (GO:0034667), signaling receptor complex (GO:0043235), postsynaptic membrane (GO:0045211), perinuclear region of cytoplasm (GO:0048471), presynaptic active zone membrane (GO:0048787), excitatory synapse (GO:0060076), extracellular exosome (GO:0070062), cell periphery (GO:0071944), synaptic membrane (GO:0097060), glutamatergic synapse (GO:0098978), growth cone filopodium (GO:1990812), membrane (GO:0016020), growth cone (GO:0030426), cell projection (GO:0042995), synapse (GO:0045202), anchoring junction (GO:0070161)

Reactome top-level categories

Rollup of top-7 pathways:

Category	Pathways
Extracellular matrix organization	2
Cell surface interactions at the vascular wall	1
MET promotes cell motility	1
Hemostasis	1
Signaling by Receptor Tyrosine Kinases	1
Signaling by MET	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
synapse	4
animal organ development	3
protein binding	3
cell-substrate adhesion	2
regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	2
protein-containing complex binding	2
binding	2
plasma membrane region	2
filopodium	2
synaptic membrane	2
cell migration	1
generation of neurons	1
cell surface receptor signaling pathway	1
small GTPase-mediated signal transduction	1
circulatory system development	1
learning or memory	1
response to chemical	1
gene expression	1
regulation of gene expression	1
positive regulation of macromolecule biosynthetic process	1
epithelial cell migration	1
regulation of epithelial cell migration	1
positive regulation of cell migration	1
regulation of cell-substrate adhesion	1
positive regulation of cell adhesion	1
regulation of neuron projection development	1
neuron projection development	1
positive regulation of cell projection organization	1
transforming growth factor beta receptor signaling pathway	1
regulation of cellular response to transforming growth factor beta stimulus	1
regulation of signal transduction	1
Wnt signaling pathway	1
respiratory tube development	1
respiratory system development	1
BMP signaling pathway	1
regulation of cellular response to growth factor stimulus	1
cell projection organization	1
regulation of cell projection organization	1
negative regulation of cellular component organization	1

Protein interactions and networks

STRING

1890 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ITGA3	ITGB1	P05556	995
ITGA3	FN1	P02751	990
ITGA3	CD151	P48509	967
ITGA3	CD9	P21926	918
ITGA3	ITGB4	P16144	890
ITGA3	ITGB5	P18084	796
ITGA3	PTK2	Q05397	784
ITGA3	ITGB3	P05106	775
ITGA3	ITGB6	P18564	745
ITGA3	LAMA3	Q16787	736
ITGA3	CD81	P18582	716
ITGA3	SRC	P12931	706
ITGA3	ITGA2	P17301	694
ITGA3	ITGAV	P06756	689
ITGA3	RICTOR	Q6R327	687

IntAct

75 interactions, top by confidence:

A	B	Type	Score
TSPAN15	ADAM10	psi-mi:“MI:0914”(association)	0.840
TSPAN5	ADAM10	psi-mi:“MI:0914”(association)	0.800
CD151	ITGA3	psi-mi:“MI:0915”(physical association)	0.760
CD151	ITGA3	psi-mi:“MI:0403”(colocalization)	0.760
ITGA3	CD151	psi-mi:“MI:0403”(colocalization)	0.760
CD9	ADAM10	psi-mi:“MI:0914”(association)	0.750
ADAM10	CD9	psi-mi:“MI:0914”(association)	0.750
TSPAN14	ADAM10	psi-mi:“MI:0914”(association)	0.740
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
SH3KBP1	USP27X	psi-mi:“MI:0914”(association)	0.640
CFTR	HAX1	psi-mi:“MI:0914”(association)	0.610
ITGA3	LGALS1	psi-mi:“MI:0915”(physical association)	0.560
SCGB1D1	FAM234B	psi-mi:“MI:0914”(association)	0.530
LGALS1	PODXL	psi-mi:“MI:0914”(association)	0.530
LGALS1	LAMA5	psi-mi:“MI:0914”(association)	0.530

BioGRID (114): ITGA3 (Affinity Capture-MS), ITGA3 (Affinity Capture-MS), FHL2 (Affinity Capture-Western), BIN1 (Two-hybrid), ITGA3 (Affinity Capture-MS), ITGA3 (Affinity Capture-MS), ITGA3 (Affinity Capture-MS), ITGA3 (Affinity Capture-MS), ITGA3 (Affinity Capture-MS), ITGA3 (Affinity Capture-Western), ITGA3 (Reconstituted Complex), ITGA3 (Affinity Capture-MS), ITGA3 (Proximity Label-MS), ITGA3 (Proximity Label-MS), RABIF (Two-hybrid)

ESM2 similar proteins: A1A5Y0, A1KZ92, A2AJ76, B0S5N4, D3YXG0, D3ZPX4, F1MMS9, O00187, O55005, O60500, O75093, O88279, O88280, P11627, P17852, P26006, P32004, P51805, P57110, P59511, P70208, P85171, Q05695, Q0PMG2, Q13219, Q3UH53, Q4KMG0, Q62470, Q62918, Q7Z5N4, Q80TR4, Q8AV58, Q8AXZ4, Q8CIY2, Q8HZK2, Q8HZK3, Q8NDA2, Q8R4K8, Q8TE57, Q91WP0

Diamond homologs: F1MMS9, P05555, P17852, P23229, P26006, P26007, P80108, P80109, Q13683, Q61738, Q61739, Q62470, Q63258, Q8R2H5, A2ARA8, O70362, O75578, P08514, P08648, P11688, P12080, P20701, P26009, P34446, P38570, P53708, Q00651, Q06274, Q13797, Q24247, Q27977, Q60677, Q91687, Q9QUM0, Q9W1M8, P13612, P06756, P43406, P80746, Q03600

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
TGFB1	“down-regulates quantity by repression”	ITGA3	“transcriptional regulation”
IL1B	“down-regulates quantity by repression”	ITGA3	“transcriptional regulation”
ITGA3	“form complex”	“A3/b1 integrin”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 69 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Signaling by Receptor Tyrosine Kinases	7	8.4×	2e-03
Axon guidance	7	7.3×	3e-03
Nervous system development	7	7.0×	3e-03
Infectious disease	9	5.2×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

625 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	5
Likely pathogenic	22
Uncertain significance	264
Likely benign	196
Benign	62

Top pathogenic / likely-pathogenic (27)

Variant ID	HGVS	Classification
209163	NM_002204.4(ITGA3):c.2070+1G>A	Pathogenic
35570	NM_002204.4(ITGA3):c.1173_1174del (p.Pro392fs)	Pathogenic
35571	NM_002204.4(ITGA3):c.1538-1G>A	Pathogenic
3675073	NM_002204.4(ITGA3):c.1528C>T (p.Arg510Ter)	Pathogenic
4535843	NM_002204.4(ITGA3):c.2577_2583+13del	Pathogenic
1344695	NM_002204.4(ITGA3):c.2593del (p.Asp865fs)	Likely pathogenic
208455	NM_002204.4(ITGA3):c.1387C>T (p.Arg463Trp)	Likely pathogenic
2631652	NM_002204.4(ITGA3):c.826C>T (p.Arg276Ter)	Likely pathogenic
2633774	NM_002204.4(ITGA3):c.2794C>T (p.Arg932Ter)	Likely pathogenic
2781185	NM_002204.4(ITGA3):c.2219+1G>A	Likely pathogenic
2869441	NM_002204.4(ITGA3):c.1469+2T>A	Likely pathogenic
3067864	NM_002204.4(ITGA3):c.*32-1G>C	Likely pathogenic
3349940	NM_002204.4(ITGA3):c.2692del (p.Ser898fs)	Likely pathogenic
3358856	NM_002204.4(ITGA3):c.821G>A (p.Arg274Gln)	Likely pathogenic
3382048	NM_002204.4(ITGA3):c.2685dup (p.Ala896fs)	Likely pathogenic
3382049	NM_002204.4(ITGA3):c.1133A>T (p.Asp378Val)	Likely pathogenic
3582231	NM_002204.4(ITGA3):c.446G>A (p.Trp149Ter)	Likely pathogenic
3582234	NM_002204.4(ITGA3):c.493C>T (p.Arg165Ter)	Likely pathogenic
3582237	NM_002204.4(ITGA3):c.665-1G>A	Likely pathogenic
3582279	NM_002204.4(ITGA3):c.2261_2264dup (p.Val756fs)	Likely pathogenic
3582280	NM_002204.4(ITGA3):c.2299del	Likely pathogenic
3582284	NM_002204.4(ITGA3):c.2401-11_2409del	Likely pathogenic
3582292	NM_002204.4(ITGA3):c.2641G>T (p.Gly881Ter)	Likely pathogenic
817532	NM_002204.4(ITGA3):c.2623C>T (p.Arg875Ter)	Likely pathogenic
818042	NM_002204.4(ITGA3):c.864_867del (p.Gly289fs)	Likely pathogenic
995569	NM_002204.4(ITGA3):c.1621G>C (p.Gly541Arg)	Likely pathogenic
996793	NM_002204.4(ITGA3):c.1912A>T (p.Lys638Ter)	Likely pathogenic

SpliceAI

3697 predictions. Top by Δscore:

Variant	Effect	Δscore
17:50056641:TACCT:T	donor_gain	1.0000
17:50056642:ACCT:A	donor_gain	1.0000
17:50056643:CCT:C	donor_gain	1.0000
17:50056644:CT:C	donor_gain	1.0000
17:50056644:CTGTA:C	donor_loss	1.0000
17:50056646:G:GG	donor_gain	1.0000
17:50056646:GTAA:G	donor_loss	1.0000
17:50064198:G:GG	donor_gain	1.0000
17:50064205:G:GG	donor_gain	1.0000
17:50068302:A:T	donor_gain	1.0000
17:50068302:AAAGG:A	donor_loss	1.0000
17:50068303:AAGG:A	donor_loss	1.0000
17:50068304:AG:A	donor_loss	1.0000
17:50068305:GGTGG:G	donor_loss	1.0000
17:50068306:GTG:G	donor_loss	1.0000
17:50070831:A:AG	acceptor_gain	1.0000
17:50070832:A:G	acceptor_gain	1.0000
17:50070833:T:G	acceptor_gain	1.0000
17:50070837:T:TA	acceptor_gain	1.0000
17:50070839:T:TA	acceptor_gain	1.0000
17:50070927:ATTGG:A	donor_loss	1.0000
17:50070928:TTGGT:T	donor_loss	1.0000
17:50070929:TG:T	donor_gain	1.0000
17:50070929:TGG:T	donor_loss	1.0000
17:50070930:GG:G	donor_gain	1.0000
17:50070930:GGT:G	donor_loss	1.0000
17:50070931:G:A	donor_loss	1.0000
17:50070931:G:GG	donor_gain	1.0000
17:50070932:T:A	donor_loss	1.0000
17:50071983:TAGGT:T	acceptor_loss	1.0000

AlphaMissense

6822 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:50068061:T:G	C140W	0.999
17:50068125:T:A	C162S	0.999
17:50068125:T:C	C162R	0.999
17:50068126:G:C	C162S	0.999
17:50068194:T:A	C185S	0.999
17:50068195:G:C	C185S	0.999
17:50076591:T:G	F611C	0.999
17:50079133:T:A	W820R	0.999
17:50079133:T:C	W820R	0.999
17:50068059:T:C	C140R	0.998
17:50068060:G:A	C140Y	0.998
17:50068069:G:C	R143P	0.998
17:50068119:G:T	G160C	0.998
17:50068120:G:T	G160V	0.998
17:50068127:C:G	C162W	0.998
17:50068230:T:C	C197R	0.998
17:50068232:C:G	C197W	0.998
17:50068301:G:C	W220C	0.998
17:50068301:G:T	W220C	0.998
17:50070844:G:T	G222V	0.998
17:50076620:T:A	C621S	0.998
17:50076621:G:C	C621S	0.998
17:50064135:G:T	G89C	0.997
17:50064150:T:A	C94S	0.997
17:50064151:G:C	C94S	0.997
17:50068120:G:A	G160D	0.997
17:50068126:G:A	C162Y	0.997
17:50068172:G:C	W177C	0.997
17:50068172:G:T	W177C	0.997
17:50068196:C:G	C185W	0.997

dbSNP variants (sampled 300 via entrez): RS1000060536 (17:50056398 C>T), RS1000105828 (17:50082097 C>T), RS1000288108 (17:50062455 C>A,T), RS1000304676 (17:50063464 C>T), RS1000541321 (17:50056738 C>A,G,T), RS1000563888 (17:50087277 G>T), RS1000623791 (17:50061140 C>G,T), RS1000678353 (17:50086979 G>A), RS1000803746 (17:50056468 G>A,C), RS1001042287 (17:50085332 A>T), RS1001060497 (17:50080652 C>T), RS1001155779 (17:50079118 G>C), RS1001196168 (17:50066963 C>T), RS1001242796 (17:50055944 A>G), RS1001292766 (17:50079455 A>G)

Disease associations

OMIM: gene MIM:605025 | disease phenotypes: MIM:614748

GenCC curated gene-disease

Disease	Classification	Inheritance
epidermolysis bullosa, junctional 7, with interstitial lung disease and nephrotic syndrome	Definitive	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
epidermolysis bullosa, junctional 7, with interstitial lung disease and nephrotic syndrome	Definitive	AR

Mondo (7): epidermolysis bullosa, junctional 7, with interstitial lung disease and nephrotic syndrome (MONDO:0013881), anemia (MONDO:0002280), phimosis (MONDO:0006904), penoscrotal transposition (MONDO:0017285), bronchopulmonary dysplasia (MONDO:0019091), respiratory failure (MONDO:0021113), nephrotic syndrome (MONDO:0005377)

Orphanet (3): Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome (Orphanet:306504), Penoscrotal transposition (Orphanet:2842), Bronchopulmonary dysplasia (Orphanet:70589)

HPO phenotypes

35 total (30 of 35 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000083	Renal insufficiency
HP:0000092	Renal tubular atrophy
HP:0000093	Proteinuria
HP:0000097	Focal segmental glomerulosclerosis
HP:0000100	Nephrotic syndrome
HP:0000160	Narrow mouth
HP:0000252	Microcephaly
HP:0000311	Round face
HP:0000316	Hypertelorism
HP:0000400	Macrotia
HP:0000448	Prominent nose
HP:0000653	Sparse eyelashes
HP:0000771	Gynecomastia
HP:0000774	Narrow chest
HP:0001030	Fragile skin
HP:0001252	Hypotonia
HP:0001806	Onycholysis
HP:0002098	Respiratory distress
HP:0002205	Recurrent respiratory infections
HP:0002209	Sparse scalp hair
HP:0002213	Fine hair
HP:0002643	Neonatal respiratory distress
HP:0003073	Hypoalbuminemia
HP:0003577	Congenital onset
HP:0003593	Infantile onset
HP:0003623	Neonatal onset
HP:0005972	Respiratory acidosis
HP:0006530	Abnormal pulmonary interstitial morphology
HP:0008066	Abnormal blistering of the skin

GWAS associations

0 associations (top):

MeSH disease descriptors (6)

Descriptor	Name	Tree numbers
D000740	Anemia	C15.378.050
D001997	Bronchopulmonary Dysplasia	C08.381.520.750.500; C16.614.521.125
D009404	Nephrotic Syndrome	C12.050.351.968.419.630.643; C12.200.777.419.630.643; C12.950.419.630.643
D010688	Phimosis	C12.100.500.494.684; C12.200.294.494.684
D012131	Respiratory Insufficiency	C08.618.846
C536650	Penoscrotal transposition (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3525 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Integrins

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
peptide ligand 2 [PMID: 19055415]	Binding	7.24	pIC50

ChEMBL bioactivities

8 potent at pChembl≥5 of 8 total, top 8 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.24	IC50	57	nM	CHEMBL2372225
7.17	IC50	68	nM	CHEMBL2372227
6.72	IC50	190	nM	CHEMBL2372226
6.66	IC50	220	nM	CHEMBL2372228
6.54	IC50	290	nM	CHEMBL510395
6.47	IC50	340	nM	CHEMBL2372229
6.40	Kd	400	nM	CHEMBL2372224
6.26	IC50	550	nM	CHEMBL2372224

PubChem BioAssay actives

8 with measured affinity, of 12 total; 7 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(6S,12R,15R,20R,23S,26S,28R)-15-amino-23-(2-amino-2-oxoethyl)-20-carbamoyl-28-hydroxy-6-[(4-hydroxy-3-nitrophenyl)methyl]-2,5,8,11,14,22,25-heptaoxo-17,18-dithia-1,4,7,10,13,21,24-heptazabicyclo[24.3.0]nonacosan-12-yl]acetic acid	411719: Binding affinity to integrin alpha3 expressed in human MDA-MB-231 cells by flow cytometry	ic50	0.0570	uM
2-[(6S,12R,15R,20R,23S,26S,28R)-15-amino-20-carbamoyl-28-hydroxy-23-[(1R)-1-hydroxyethyl]-6-[(4-hydroxy-3-nitrophenyl)methyl]-2,5,8,11,14,22,25-heptaoxo-17,18-dithia-1,4,7,10,13,21,24-heptazabicyclo[24.3.0]nonacosan-12-yl]acetic acid	411719: Binding affinity to integrin alpha3 expressed in human MDA-MB-231 cells by flow cytometry	ic50	0.0680	uM
2-[(6S,12R,15R,20R,23S,26S,28R)-15-amino-20-carbamoyl-28-hydroxy-23-(2-hydroxyethyl)-6-[(4-hydroxy-3-nitrophenyl)methyl]-2,5,8,11,14,22,25-heptaoxo-17,18-dithia-1,4,7,10,13,21,24-heptazabicyclo[24.3.0]nonacosan-12-yl]acetic acid	411719: Binding affinity to integrin alpha3 expressed in human MDA-MB-231 cells by flow cytometry	ic50	0.1900	uM
2-[(6S,12R,15R,20R,23S,26S,28R)-15-amino-20-carbamoyl-6-[(3-chlorophenyl)methyl]-28-hydroxy-23-[(1R)-1-hydroxyethyl]-2,5,8,11,14,22,25-heptaoxo-17,18-dithia-1,4,7,10,13,21,24-heptazabicyclo[24.3.0]nonacosan-12-yl]acetic acid	411719: Binding affinity to integrin alpha3 expressed in human MDA-MB-231 cells by flow cytometry	ic50	0.2200	uM
2-[(6S,12R,15R,20R,23S,26S)-15-amino-20-carbamoyl-6-(cyclohexylmethyl)-23-methyl-2,5,8,11,14,22,25-heptaoxo-17,18-dithia-1,4,7,10,13,21,24-heptazabicyclo[24.3.0]nonacosan-12-yl]acetic acid	411719: Binding affinity to integrin alpha3 expressed in human MDA-MB-231 cells by flow cytometry	ic50	0.2900	uM
2-[(6S,12R,15R,20R,23S,26S,28R)-15-amino-20-carbamoyl-6-(cyclohexylmethyl)-28-hydroxy-2,5,8,11,14,22,25-heptaoxo-23-(2-phenylethyl)-17,18-dithia-1,4,7,10,13,21,24-heptazabicyclo[24.3.0]nonacosan-12-yl]acetic acid	411719: Binding affinity to integrin alpha3 expressed in human MDA-MB-231 cells by flow cytometry	ic50	0.3400	uM
2-[(6S,12R,15R,20R,23S,26S,28R)-15-amino-23-(2-amino-2-oxoethyl)-20-carbamoyl-28-hydroxy-6-(2-methylpropyl)-2,5,8,11,14,22,25-heptaoxo-17,18-dithia-1,4,7,10,13,21,24-heptazabicyclo[24.3.0]nonacosan-12-yl]acetic acid	411712: Binding affinity to integrin alpha3beta1 expressed in human MDA-MB-231 cells by flow cytometry	kd	0.4000	uM

CTD chemical–gene interactions

103 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tobacco Smoke Pollution	affects expression, decreases expression, increases expression	4
Aflatoxin B1	affects expression, decreases methylation, increases expression	4
Benzo(a)pyrene	decreases expression, increases expression, increases methylation	3
Cisplatin	affects expression, increases expression	3
Copper	affects binding, decreases expression, increases expression	3
manganese chloride	increases expression, affects cotreatment, decreases expression, increases abundance	2
Troglitazone	increases expression	2
Acetaminophen	increases expression	2
Air Pollutants	increases expression, affects cotreatment, decreases expression, increases abundance	2
Cadmium	increases expression, affects binding, increases activity, increases reaction	2
Calcitriol	increases expression, affects cotreatment	2
Estradiol	increases expression, affects cotreatment	2
Lipopolysaccharides	affects expression, affects response to substance, affects cotreatment, decreases expression	2
Manganese	increases expression, affects cotreatment, decreases expression, increases abundance	2
Ozone	affects cotreatment, decreases expression, increases abundance, increases expression, increases oxidation	2
Cyclosporine	increases expression	2
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
propionaldehyde	increases expression	1
bisphenol A	affects cotreatment, decreases expression	1
lead acetate	increases expression	1
methylselenic acid	increases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, increases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
dimethylselenide	increases expression, increases oxidation, decreases expression	1
beta-lapachone	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	decreases expression, increases abundance, affects cotreatment	1
benzo(e)pyrene	decreases methylation	1

ChEMBL screening assays

5 unique, capped per target: 5 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1012891	Binding	Binding affinity to integrin alpha3 expressed in human MDA-MB-231 cells at 15 mins by flow cytometry in presence of 0.5 ug/mL anti-integrin alpha3 antibody	Discovery of targeting ligands for breast cancer cells using the one-bead one-compound combinatorial method. — J Med Chem

Cellosaurus cell lines

6 cell lines: 6 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1X0	Abcam A-549 ITGA3 KO	Cancer cell line	Male
CVCL_D2BB	Abcam HCT 116 ITGA3 KO	Cancer cell line	Male
CVCL_D7SL	Ubigene A-549 ITGA3 KO	Cancer cell line	Male
CVCL_E0FG	Ubigene HeLa ITGA3 KO	Cancer cell line	Female
CVCL_ST25	HAP1 ITGA3 (-) 1	Cancer cell line	Male
CVCL_ST26	HAP1 ITGA3 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00003398	PHASE4	COMPLETED	Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
NCT00022386	PHASE4	COMPLETED	Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer
NCT00046969	PHASE4	COMPLETED	Epoetin Beta in Treating Anemia in Patients With Cervical Cancer
NCT00111995	PHASE4	COMPLETED	Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis
NCT00117039	PHASE4	COMPLETED	A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia
NCT00117065	PHASE4	COMPLETED	Study of Transplant Related Anemia Treated With Aranesp® (STRATA)
NCT00117117	PHASE4	COMPLETED	A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®
NCT00126334	PHASE4	COMPLETED	Conservative Versus Liberal Red Cell Transfusion in Myocardial Infarction Trial: The CRIT Pilot
NCT00153868	PHASE4	COMPLETED	A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer
NCT00168948	PHASE4	UNKNOWN	Intermittent Antimalaria Treatment With SP in African Children
NCT00173706	PHASE4	UNKNOWN	Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis
NCT00194857	PHASE4	TERMINATED	Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin
NCT00204334	PHASE4	COMPLETED	Effects of Anemia Correction on Vascular and Monocyte Function in Renal Transplant Recipients
NCT00206739	PHASE4	COMPLETED	Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infants
NCT00211120	PHASE4	TERMINATED	Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)
NCT00216541	PHASE4	COMPLETED	A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy
NCT00223938	PHASE4	TERMINATED	Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.
NCT00223964	PHASE4	COMPLETED	Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients
NCT00224003	PHASE4	COMPLETED	Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients
NCT00224068	PHASE4	COMPLETED	Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy
NCT00239642	PHASE4	COMPLETED	Safety and Efficacy of Iron Sucrose in Children
NCT00247507	PHASE4	UNKNOWN	The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients
NCT00248716	PHASE4	UNKNOWN	Treatment of Anemia in the 2nd Year of Life. Comparison of the Efficacy of Two Different Iron Preparations.
NCT00283465	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy
NCT00312871	PHASE4	TERMINATED	Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency
NCT00315484	PHASE4	COMPLETED	Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia
NCT00317902	PHASE4	COMPLETED	An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)
NCT00335023	PHASE4	COMPLETED	Well Being of Obstetric Patients on Minimal Blood Transfusions
NCT00338468	PHASE4	TERMINATED	A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)
NCT00377481	PHASE4	COMPLETED	COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
NCT00396435	PHASE4	COMPLETED	Correction of Anaemia and Progression of Renal Failure on Transplanted Patients
NCT00401869	PHASE4	COMPLETED	The Effect of PROCRIT (Epoetin Alfa) on Postoperative Vigor and Handgrip Strength (VIGOR Study)
NCT00413101	PHASE4	COMPLETED	A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.
NCT00431496	PHASE4	COMPLETED	A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)
NCT00437723	PHASE4	COMPLETED	A Study of NeoRecormon in Patients With Chronic Kidney Disease.
NCT00440063	PHASE4	TERMINATED	A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia.
NCT00470158	PHASE4	COMPLETED	Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical Outcomes
NCT00479102	PHASE4	UNKNOWN	Prevention of Iron Deficiency in 2nd Year of Life
NCT00495365	PHASE4	TERMINATED	A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.
NCT00495378	PHASE4	TERMINATED	RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia